Literature DB >> 26824958

Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.

Henry S Heine1, Lara Chuvala2, Renaldo Riggins2, Ryan Cirz3, Robert Cass3, Arnold Louie2, G L Drusano2.   

Abstract

The objective of this study was to evaluate the natural history and pathogenesis of Francisella tularensis in a murine model of inhalational tularemia with the SchuS4 strain. Before the efficacy of antimicrobials could be assessed in this model, further model development was required to determine the optimal time to start therapy. This study helped define the time course of infection after aerosol challenge by quantifying the presence of bacteria in lung, blood, and spleen at multiple harvest points. In this study, mice were infected via a targeted inhaled dose of 100 50% lethal doses (LD50s) (LD50 = 300 CFU) of F. tularensis by whole-body aerosol. At 1, 24, 36, 48, 60, 72, 75, 78, 81, 84, 87, and 90 h postchallenge, groups of 15 animals were sacrificed and blood, lung, and splenic tissue samples were harvested, homogenized, plated, and incubated to evaluate the bacterial load in those tissues. It was determined that of the 3 sample types harvested, splenic tissue provided the most consistent bacterial counts, which steadily increased with the progressing infection. Further, it was determined that lung samples from all (15/15) animals were positive for infection at 75 h postaerosolization and that 14/15 animals had positive splenic tissue counts. Bacterial levels in blood were not predictive of treatment initiation. For future therapeutic evaluation studies in this model using F. tularensis (SchuS4), it was determined that therapy should be initiated at 75 h postchallenge and validated by spleen involvement.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26824958      PMCID: PMC4775995          DOI: 10.1128/AAC.02887-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Measurement of the respiratory volumes of laboratory animals.

Authors:  A C GUYTON
Journal:  Am J Physiol       Date:  1947-07-01

2.  Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

Authors:  George Louis Drusano; Weiguo Liu; Steven Fikes; Ryan Cirz; Nichole Robbins; Stephanie Kurhanewicz; Jaime Rodriquez; David Brown; Dodge Baluya; Arnold Louie
Journal:  J Infect Dis       Date:  2014-04-22       Impact factor: 5.226

3.  The syndrome of pneumococcemia, disseminated intravascular coagulation and asplenia.

Authors:  M E Kingston; C R MacKenzie
Journal:  Can Med Assoc J       Date:  1979-07-07       Impact factor: 8.262

4.  Antibiotic treatment of experimental pneumonic plague in mice.

Authors:  W R Byrne; S L Welkos; M L Pitt; K J Davis; R P Brueckner; J W Ezzell; G O Nelson; J R Vaccaro; L C Battersby; A M Friedlander
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Justin M Hartings; Bruce E Ivins; M Louise Pitt; David Fritz; Sarah L Norris; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

6.  Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

Authors:  G L Drusano; Christine Fregeau; Weiguo Liu; D L Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

7.  The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression.

Authors:  Audrey Chong; Tara D Wehrly; Vinod Nair; Elizabeth R Fischer; Jeffrey R Barker; Karl E Klose; Jean Celli
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

8.  Pneumococcal bacteremia at a medical/surgical hospital for adults between 1975 and 1980.

Authors:  F L Ruben; C W Norden; Y Korica
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

9.  Use of temperature for standardizing the progression of Francisella tularensis in mice.

Authors:  Claudia R Molins; Mark J Delorey; John W Young; Brook M Yockey; John T Belisle; Martin E Schriefer; Jeannine M Petersen
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

10.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03
View more
  4 in total

1.  The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.

Authors:  Trudy H Grossman; Michael S Anderson; David Christ; Melanie Gooldy; Lisa N Henning; Henry S Heine; M Victoria Kindt; Winston Lin; Kaylyn Siefkas-Patterson; Anne K Radcliff; Vincent H Tam; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Rapid viability polymerase chain reaction method for detection of Francisella tularensis.

Authors:  Staci R Kane; Sanjiv R Shah; Teneile M Alfaro
Journal:  J Microbiol Methods       Date:  2019-10-15       Impact factor: 2.363

3.  A spontaneous mutation in kdsD, a biosynthesis gene for 3 Deoxy-D-manno-Octulosonic Acid, occurred in a ciprofloxacin resistant strain of Francisella tularensis and caused a high level of attenuation in murine models of tularemia.

Authors:  Taylor Chance; Jennifer Chua; Ronald G Toothman; Jason T Ladner; Jonathan E Nuss; Jo Lynne Raymond; Fabrice V Biot; Samandra Demons; Lynda Miller; Stephanie Halasohoris; Sherry Mou; Galina Koroleva; Sean Lovett; Gustavo Palacios; Nicholas J Vietri; Patricia L Worsham; Christopher K Cote; Todd M Kijek; Joel A Bozue
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

4.  Validated Methods for Removing Select Agent Samples from Biosafety Level 3 Laboratories.

Authors:  Alexandria E Kesterson; John E Craig; Lara J Chuvala; Henry S Heine
Journal:  Emerg Infect Dis       Date:  2020-11       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.